1. Market Research
  2. > Pharmaceutical Market Trends
Active Pharmaceutical Ingredients (API) Global Market – Forecast To 2025

Active Pharmaceutical Ingredients (API) Global Market – Forecast To 2025

  • May 2019
  • 626 pages
  • ID: 3844910
  • Format: PDF
  • IQ4I Research & Consultancy Pvt. Ltd

Summary

Table of Contents

Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having direct effect on disease treatment.

APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from natural source. According to IQ4I analysis, the global Active Pharmaceutical Ingredient market is expected to grow at a high CAGR to reach $307.2 billion by 2025. Adoption of biologics in disease management and increasing regulatory approvals in the past year, increasing scope of HPAPI market, patent expiration of major drugs, increasing trend of outsourcing and increase in geriatric population are some of the factors driving the market growth. The global API market is mainly segmented by synthesis, by business type, by application and by geography.

API market based on synthesis is further divided into synthetic API, Biotech API and HPAPI. Synthetic API holds major share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in incidence of chronic and age-related diseases, rapid growth in oncology market, technological advancement like cryogenic and continuous flow manufacturing. Based on the customer, the synthetic API is further divided into branded API and generic API. Branded API accounted the largest share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. Generic API is expected to grow at a high single digit CAGR from 2018 to 2025, due to Patent expiry of blockbuster drugs, rising healthcare expenses, increasing outsourcing and shift towards the generic medicines led by the government initiatives.

Biotech API is expected to grow at a high single digit CAGR from 2018 to 2025. Increased investment in R&D by pharmaceutical companies for developing biologic drugs, adoption of biological therapies in disease management, increasing outsourcing, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, increasing number of branded drugs going off-patent creating a scope for biosimilars, requirement of novel biologics therapeutics for rare diseases, increasing demand for antibody conjugates are few factors driving the biotech API market. Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines and others (stem cell therapy and gene therapy). Monoclonal antibodies accounted for highest share in 2018 and expected to grow at a double digit CAGR from 2018 to 2025. Development of next generation antibodies such as antibody-drug conjugates and rising venture capital investments and applications of monoclonal antibodies are the factors booming monoclonal antibodies market growth. Based on the customer, biotech API is further divided into biologics and biosimilars. Biologics accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025. Biologics market is driven globally due to adoption of biological therapies in disease management, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses and increasing elderly population globally. Biosimilars is expected to grow at a mid double digit CAGR from 2018 to 2025. Factors driving the biosimilar drug market are patent expiry of biological drugs, low cost compared to biologics health care expenditure, increase in chronic diseases, growing geriatric population, demand for quality healthcare.

HPAPI is expected to grow at a high single digit CAGR from 2018 to 2025. Rapid growth in oncology market, low toxicity and lower side effects, technological advancements in HPAPI, increasing outsourcing, increasing incidence of chronic and age related diseases are few factors driving the HPAPI market growth. Based on customer, HPAPI is further divided into branded API and generic API. Branded API is accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025, increased development of targeted therapy APIs, increased investments in the manufacturing of branded HPAPI are the factors driving the market. Generic API is expected to grow at a high single digit CAGR from 2018 to 2025. Patent expiry of blockbuster drugs, rising healthcare expenses and shift towards the generic medicines led by the government initiatives are some of the factors driving the generic HPAPI market.

By business type, global API market is divided into captive API and merchant API. Captive market holds major share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025, captive API is further divided into branded captive API and generic captive API, branded captive API accounted the largest share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. Merchant API market is fastest growing segment with a high single digit CAGR from 2018 to 2025. Novel drugs patent expiry, high cost of innovative drugs and complications in innovative drug manufacturing are some of the factors driving the growth of Merchant API market. Merchant API market is further divided into branded merchant API and generic merchant API. Generic merchant API accounted the largest share in 2018 and is expected to grow at a double digit CAGR from 2018 to 2025. Increasing outsourcing, advanced manufacturing facilities, lack of in-house manufacturing capability, high capital investment and cost of API manufacturing are the factors driving Merchant API market.

By therapeutic applications, API market is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculo-skeletal disorders and others. In application segment, Oncology holds major share in 2018 and expected to grow at a high single digit CAGR from 2018 to 2025. In synthetic API, infectious diseases accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025, oncology is expected to grow at a high single digit CAGR from 2018 to 2025. In biotech API, musculoskeletal disorders accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025, oncology is expected to grow at a double digit CAGR from 2018 to 2025. In HPAPI, oncology accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025. Biotech API and HPAPI is driving the market growth at faster pace due to rising targeted therapy demand in last 15 years for treatment of diseases mainly in oncology sector.

Active pharmaceutical Ingredients market by region is segmented as North America, Europe, Asia-Pacific and Rest of the world (ROW) where North America holds largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025. Patent expiration of the major drugs, rising demand for biotech APIs from government and private companies, market entry of biosimilars, increasing scope of high potent drugs and increase in the prevalence of chronic diseases such as cancer, musculoskeletal disorder, cardiac disease are some of the major factors driving the North America API market. Asia-Pacific region is expected to grow at a high single digit CAGR from 2018 to 2025. Low labor cost, abundance availability of raw materials, infrastructure facility, rise in generic drugs demand, increased production capabilities, the presence of large number of domestic and international players, and concentration of CMO companies are some of the factors that are driving the market growth.

Some of the key players of Active pharmaceutical Ingredient (API) market are Lonza Group (Switzerland), Boehringer Ingelheim GmbH (Germany), Teva Pharmaceutical Industries LTD (Israel), Sanofi (France), Patheon N.V (U.S), Aurobindo pharmaceuticals. (India), Seigfried Holdings A.G (Switzerland), Olon S.p.A (Italy), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Cambrex Corporation (U.S.) and AMRI, (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Rest of North America

• Europe
o Italy
o Germany
o France
o Rest of Europe

• Asia-Pacific
o China
o Japan
o India
o Rest of APAC

• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle East and Others

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Hypertension Drugs Markets in China

  • $ 4000
  • September 2020
  • 215 pages

China’s demand for Hypertension Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...

  • United States
  • World
  • Biotechnology
  • Pharmaceutical
  • Quarterly report
  • Company
  • Number Of Enterprises
  • Book Sales

Global Marine Biotechnology Industry $ 5600 September 2020


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on